Introduction {#s1}
============

Although many studies have investigated the etiology of moyamoya disease, unsatisfactory progress has been made. Moyamoya disease etiology may be idiopathic, environmental, or genetic. The search for genetic loci linked to moyamoya disease has uncovered associations with chromosomes 3, 6, 7, 8, and 17 and the HLA haplotype [@pone.0047158-Kang1]--[@pone.0047158-Park1], but relevant genes have not been identified [@pone.0047158-Nanba1]. Recent linkage analyses from East Asian families with moyamoya disease demonstrated a linkage of 17q25.3 with the disease at a locus that is −1480 bp from the transcription site of the Raptor gene. However, an allele of this gene was not detected in samples from Caucasian patients with this disease [@pone.0047158-Liu1].

Vascular endothelial growth factor (VEGF) is involved in vasculogenesis and vascular permeability in various intracranial lesions [@pone.0047158-Sakamoto1]. In ischemic disease, cerebral angiogenesis is caused by the release of VEGF [@pone.0047158-Cao1], [@pone.0047158-Jin1]. VEGF affects vasculogenesis, endothelial cell proliferation and migration, vascular permeability, and stromal degradation through the activation of proteolytic enzymes that are involved in angiogenesis [@pone.0047158-Mukhopadhyay1], [@pone.0047158-Ikeda2]. VEGF binds its receptor tyrosine kinases, VEGF receptor-1 and VEGF receptor-2 (also known as kinase insert domain containing receptor, or KDR) but KDR is the key receptor mediating angiogenesis [@pone.0047158-Waltenberger1] and is essential for endothelial cell survival and integrity [@pone.0047158-Gerber1].

Although excess VEGF in moyamoya disease has been demonstrated [@pone.0047158-Sakamoto1], [@pone.0047158-Takekawa1] and the association is convincing, the specific role for *VEGF* remains unclear. Therefore, we studied the relationship of *VEGF* and *KDR* polymorphisms and moyamoya disease. VEGF is a major angiogenic factor and a prime regulator of endothelial cell proliferation [@pone.0047158-LaRosa1]. The gene that encodes *VEGF* is located on chromosome 6 and is comprised of a 14-kb coding region with eight exons and seven introns [@pone.0047158-Vincenti1]. VEGF is activated transcriptionally and posttranscriptionally by hypoxia in tumor necrosis and in various models of ischemia [@pone.0047158-Leung1], [@pone.0047158-Shweiki1]. Ischemia stimulates *VEGF* expression in the brain suggesting that it may be important for the vascular response to cerebral ischemia [@pone.0047158-Kovacs1], [@pone.0047158-Hayashi1], [@pone.0047158-Lennmyr1]. Several single nucleotide polymorphisms (SNPs) have been described in the *VEGF* gene (National Center for Biotechnology Information, Gene association no: NT 007592). The *VEGF* gene includes at least 4 relatively common polymorphisms that may influence *VEGF* expression: −2578C\>A (rs699947), −1154G\>A (rs1570360), −634G\>C (rs2010963), and 936C\>T (rs3025039) [@pone.0047158-Brogan1], [@pone.0047158-Awata1], [@pone.0047158-Renner1].

10.1371/journal.pone.0047158.t001

###### Demographic characteristics between controls and moyamoya patients.

![](pone.0047158.t001){#pone-0047158-t001-1}

  Characteristic                                Control (n = 243)   Moyamoya(n = 107)   *P* [\*](#nt101){ref-type="table-fn"}   Ischemicmoyamoya(n = 92)   Hemorrhagic moyamoya(n = 15)   *P* [\*](#nt101){ref-type="table-fn"}
  -------------------------------------------- ------------------- ------------------- --------------------------------------- -------------------------- ------------------------------ ---------------------------------------
  Number of subjects                                                                                                                                                                     
  \<18 years                                       102 (42.0)           56 (52.3)                                                      54 (58.7)                     2 (13.3)            
  ≥18 years                                        141 (58.0)           51 (47.7)                                                      38 (41.3)                    13 (86.7)            
  Age (means±SD)                                                                                                                                                                         
  \<18 years                                        7.71±4.05           7.98±4.13                       0.920                          8.11±4.12                    4.50±3.54                              NA
  ≥18 years                                        36.72±10.05         34.98±11.29                      0.248                         34.63±11.45                  36.00±11.21                            0.689
  Sex \[male, n(%)\]                                                                                                                                                                     
  \<18 years                                        54 (52.9)           22 (39.3)                       0.100                          21 (38.9)                     1 (50.0)             1.000[†](#nt102){ref-type="table-fn"}
  ≥18 years                                         51 (21.0)           14 (27.5)                       0.260                          12 (31.6)                     2 (15.4)             0.472[†](#nt102){ref-type="table-fn"}
  Collateral vessel formation score (n = 64)                                                                                                                                             
  0                                                    --                   2                                                                                                            
  1                                                    --                  22                                                                                                            
  2                                                    --                  40                                                                                                            

*P* values were calculated using the Mann-Whitney test for continuous data and χ^2^-test for categorical data.

Fisher\'s exact test. NA; not applicable.

Three of these polymorphisms are located in the promoter region at −2578, −1154, and −634 relative to the translation start site. The −2578A, −1154A, and −634G alleles are all associated with decreased *VEGF* expression [@pone.0047158-Brogan1], [@pone.0047158-Awata1]. In addition to promoter region polymorphisms, the T allele of the common 936C\>T polymorphism in the 3′-untranslated region is also associated with significantly decreased serum VEGF levels [@pone.0047158-Renner1]. Recently, several SNPs of the VEGF gene have been associated with cancer risk and prognosis [@pone.0047158-Schneider1], as well as coronary arterial disease [@pone.0047158-Petrovic1]. Moreover, *KDR* −604C, 1192A, and 1719A alleles of chromosome 4 were associated with decreased VEGF binding activity and coronary artery disease [@pone.0047158-Wang1]. These results indicate the importance of VEGF-KDR signaling in human disease.

![Linkage disequilibrium(LD) of VEGF and KDR polymorphisms.\
There was strong LD between −1154G\>A (rs 1570460) and −634G\>C (rs2010963) (D′ = 0.92), −2578C\>A (rs 699947)and 1154G\>A (rs1570360) (D′ = 0.89). There was strong LD between 1719T\>A(rs1870377) and 1192G\>A (rs2305948) (D′ = 0.79).](pone.0047158.g001){#pone-0047158-g001}

10.1371/journal.pone.0047158.t002

###### The frequencies of the *VEGF* −2578C\>A, −1154G\>A, −634G\>C, and 936C\>T polymorphisms between control subjects and patients with moyamoya disease.

![](pone.0047158.t002){#pone-0047158-t002-2}

  Characteristics             Controls (n = 243, %)   Moyamoya patients (n = 107, %)       AOR (95% CI)       *P* [\*](#nt103){ref-type="table-fn"}
  -------------------------- ----------------------- -------------------------------- ---------------------- ---------------------------------------
  *VEGF* −2578C\>A                                                                                           
  CC                               128 (52.7)                   62 (57.9)               1.000 (reference)    
  CA                                99 (40.7)                   36 (33.6)              0.769 (0.470--1.258)                   0.296
  AA                                16 (6.6)                     9 (8.4)               1.188 (0.491--2.873)                   0.702
  Dominant (CC vs. CA+AA)                                                              0.827 (0.520--1.315)                   0.422
  Recessive (CC+CA vs. AA)                                                             1.296 (0.547--3.072)                   0.556
  *VEGF--*1154G\>A                                                                                           
  GG                               173 (71.2)                   80 (74.8)               1.000 (reference)    
  GA                                62 (25.5)                   25 (23.4)              0.873 (0.510--1.496)                   0.622
  AA                                 8 (3.3)                     2 (1.9)               0.517 (0.106--2.519)                   0.414
  Dominant (GG vs. GA+AA)                                                              0.834 (0.495--1.405)                   0.495
  Recessive (GG+GA vs. AA)                                                             0.546 (0.113--2.653)                   0.454
  *VEGF* −634G\>C                                                                                            
  GG                                90 (37.0)                   37 (34.6)               1.000 (reference)    
  GC                                103(42.4)                   48 (44.9)              1.127 (0.666--1.906)                   0.655
  CC                                50 (20.6)                   22 (20.6)              1.083 (0.575--2.042)                   0.804
  Dominant (GG vs. GC+CC)                                                              1.124 (0.695--1.817)                   0.634
  Recessive (GG+GC vs. CC)                                                             1.024 (0.579--1.811)                   0.934
  *VEGF* 936C\>T                                                                                             
  CC                               172 (70.8)                   67 (62.6)               1.000 (reference)    
  CT                                64 (26.3)                   37 (34.6)              1.530 (0.926--2.529)                   0.097
  TT                                 7 (2.9)                     3 (2.8)               1.230 (0.301--5.027)                   0.773
  Dominant (CC vs. CT+TT)                                                              1.484 (0.912--2.416)                   0.112
  Recessive (CC+CT vs. TT)                                                             1.079 (0.270--4.313)                   0.915

Adjusted by age and gender. AOR, adjusted odds ratio. CI, confidence interval.

To our knowledge, no previous study has evaluated both *KDR* and *VEGF* polymorphisms with moyamoya disease and collateral vessel formation after surgery. The aim of present study was to evaluate the frequencies of the *VEGF* −2578C\>A, −1154G\>A, −634G\>C, and 936C\>T and *KDR* −604T\>C (rs2071559), 1192G\>A (rs2305948), and 1719T\>A (rs1870377) polymorphisms in Korean patients with moyamoya disease in an effort to determine the relationship of these polymorphisms with moyamoya disease.

10.1371/journal.pone.0047158.t003

###### The frequencies of the *KDR* −604T\>C, 1192G\>A, and 1719T\>A polymorphisms between control subjects and patients with moyamoya disease.

![](pone.0047158.t003){#pone-0047158-t003-3}

  Characteristics             Controls (n = 243, %)   Moyamoya patients (n = 107, %)       AOR (95% CI)       *P* [\*](#nt104){ref-type="table-fn"}
  -------------------------- ----------------------- -------------------------------- ---------------------- ---------------------------------------
  *KDR* −604T\>C                                                                                             
  TT                               113 (46.5)                   47 (43.9)               1.000 (reference)    
  TC                               108 (44.4)                   50 (46.7)              1.131 (0.698--1.833)                   0.617
  CC                                22 (9.1)                     10 (9.3)              1.102 (0.482--2.517)                   0.818
  Dominant (CC vs. CA+AA)                                                              1.128 (0.710--1.792)                   0.609
  Recessive (CC+CA vs. AA)                                                             1.039 (0.470--2.296)                   0.925
  *KDR* 1192G\>A                                                                                             
  GG                               186 (76.5)                   80 (74.8)               1.000 (reference)    
  GA                                52 (21.4)                   22 (20.6)              0.994 (0.563--1.754)                   0.983
  AA                                 5 (2.1)                     5 (4.7)               2.140 (0.596--7.693)                   0.244
  Dominant (GG vs. GA+AA)                                                              1.101 (0.646--1.875)                   0.725
  Recessive (GG+GA vs. AA)                                                             2.139 (0.597--7.665)                   0.243
  *KDR* 1719T\>A                                                                                             
  TT                                46 (18.9)                   26 (24.3)               1.000 (reference)    
  TA                               114 (46.9)                   45 (42.1)              0.764 (0.417--1.401)                   0.384
  AA                                83 (34.2)                   36 (33.6)              0.799 (0.427--1.495)                   0.482
  Dominant (TT vs. TA+AA)                                                              0.775 (0.446--1.346)                   0.365
  Recessive (TT+TA vs. AA)                                                             0.997 (0.613--1.620)                   0.989

Adjusted by age and gender. AOR, adjusted odds ratio. CI, confidence interval.

Methods {#s2}
=======

Subjects {#s2a}
--------

One hundred seven consecutive Korean patients with moyamoya disease \[mean age, 20.9±15.9 years; 71 females (66.4%), 36 males (33.6%)\] were recruited for this study. Moyamoya disease was defined as the presence of clinical ischemic or hemorrhagic symptoms in combination with vascular lesions in magnetic resonance imaging (MRI) or magnetic resonance angiography (MRA).

10.1371/journal.pone.0047158.t004

###### The frequency of the *VEGF* polymorphisms according to age.

![](pone.0047158.t004){#pone-0047158-t004-4}

                              Age \<18 years   Age ≥18 years                                                                                   
  -------------------------- ---------------- --------------- ----------------------- ------- ------------ ----------- ----------------------- -------
  *VEGF* −2578C\>A                                                                                                                             
  CC                            57 (55.9)        29 (51.8)       1.000 (reference)             71 (50.4)    33 (64.7)     1.000 (reference)    
  CA                            42 (41.2)        22 (39.3)     1.100 (0.548--2.206)    0.789   57 (40.4)    14 (27.5)   0.539 (0.261--1.113)    0.095
  AA                             3 (2.9)          5 (8.9)      3.191 (0.696--14.631)   0.135    13 (9.2)     4 (7.8)    0.669 (0.200--2.242)    0.514
  Dominant (CC vs. CA+AA)                                      1.246 (0.638--2.433)    0.519                            0.543 (0.277--1.063)    0.075
  Recessive (CC+CA vs. AA)                                     3.044 (0.686--13.499)   0.143                            0.777 (0.239--2.525)    0.674
  *VEGF* −1154G\>A                                                                                                                             
  GG                            77 (75.5)        44 (78.6)       1.000 (reference)             109 (77.3)   36 (70.6)     1.000 (reference)    
  GA                            22 (21.6)        9 (16.1)      1.614 (0.755--3.449)    0.217   30 (21.3)    13 (25.5)   0.391 (0.160--0.957)    0.040
  AA                             3 (2.9)          3 (5.4)      0.695 (0.067--7.200)    0.760    2 (1.4)      2 (3.9)    0.445 (0.049--4.029)    0.472
  Dominant (GG vs. GA+AA)                                      1.522 (0.729--3.178)    0.264                            0.395 (0.169--0.923)    0.032
  Recessive (GG+GA vs. AA)                                     0.608 (0.061--6.044)    0.671                            0.517 (0.058--4.589)    0.554
  *VEGF* −634G\>C                                                                                                                              
  GG                            34 (33.3)        24 (42.9)       1.000 (reference)             56 (39.7)    13 (25.5)     1.000 (reference)    
  GC                            46 (45.1)        27 (48.2)     0.813 (0.398--1.664)    0.571   57 (40.4)    21 (41.2)   1.715 (0.771--3.816)    0.186
  CC                            22 (21.6)         5 (8.9)      0.301 (0.096--0.946)    0.040   28 (19.9)    17 (33.3)   2.698 (1.137--6.403)    0.024
  Dominant (GG vs. GC+CC)                                      0.644 (0.236--1.273)    0.206                            2.016 (0.979--4.152)    0.057
  Recessive (GG+GC vs. CC)                                     0.334 (0.117--0.955)    0.041                            2.087 (1.014--4.295)    0.046
  *VEGF* 936C\>T                                                                                                                               
  CC                            76 (74.5)        38 (67.9)       1.000 (reference)             96 (68.1)    31 (60.8)     1.000 (reference)    
  CT                            24 (23.5)        18 (32.1)     1.580 (0.756--3.303)    0.224   41 (29.1)    17 (33.3)   1.322 (0.652--2.681)    0.438
  TT                             2 (2.0)          0 (0.0)               NA              NA      4 (2.8)      3 (5.9)    2.562 (0.525--12.506)   0.245
  Dominant (CC vs. CT+TT)                                      1.405 (0.681--2.900)    0.357                            1.378 (0.702--2.702)    0.351
  Recessive (CC+CT vs. TT)                                                                                              2.207 (0.472--10.328)   0.315

Adjusted by age and gender. NA; not applicable. AOR, adjusted odds ratio. CI, confidence interval.

The control group was comprised of 243 healthy subjects \[mean age, 23.0±16.1 years; 138 female (56.8%); 105 male (43.2%)\] from the same geographic region as the moyamoya patients. These age- and sex-matched subjects were recruited from outpatient clinics at Severance Hospital (Seoul, Korea) and CHA Bundang Medical Center (Seongnam, Korea).

10.1371/journal.pone.0047158.t005

###### The frequency of the *KDR* polymorphisms according to age.

![](pone.0047158.t005){#pone-0047158-t005-5}

                              Age \<18 years   Age ≥18 years                                                                                   
  -------------------------- ---------------- --------------- ----------------------- ------- ------------ ----------- ----------------------- -------
  *KDR* −604T\>C                                                                                                                               
  CC                            54 (52.9)        25 (44.6)       1.000 (reference)             59 (41.8)    22 (43.1)     1.000 (reference)    
  CA                            40 (39.2)        27 (48.2)      1.413(0.711--2.808)    0.324   68 (48.2)    23 (45.1)   0.929 (0.467--1.847)    0.833
  AA                             8 (7.8)          4 (7.1)       1.096(0.298--4.031)    0.890    14 (9.9)    6 (11.8)    1.141 (0.388--3.356)    0.811
  Dominant (CC vs. CA+AA)                                       1.350(0.697--2.616)    0.374                            0.951 (0.495--1.826)    0.879
  Recessive (CC+CA vs. AA)                                      0.889(0.251--3.143)    0.855                            1.198 (0.433--3.320)    0.728
  *KDR* 1192G\>A                                                                                                                               
  GG                            20 (19.6)        16 (28.6)       1.000 (reference)             26 (18.4)    10 (19.6)     1.000 (reference)    
  GA                            47 (46.1)        22 (39.3)     0.572 (0.246--1.323)    0.193   67 (47.5)    23 (45.1)   1.082 (0.440--2.664)    0.864
  AA                            35 (34.2)        18 (32.1)     0.654 (0.232--1.572)    0.342   48 (34.0)    18 (35.3)   0.965 (0.382--2.435)    0.940
  Dominant (GG vs. GA+AA)                                      0.611 (0.284--1.313)    0.207                            1.003 (0.440--2.286)    0.994
  Recessive (GG+GA vs. AA)                                     0.927 (0.460--1.869)    0.833                            1.069 (0.543--2.103)    0.848
  *KDR* 1719T\>A                                                                                                                               
  TT                            77 (75.5)        44 (78.6)       1.000 (reference)             109 (77.3)   36 (70.6)     1.000 (reference)    
  TA                            22 (21.6)        9 (16.1)      0.739 (0.310--1.762)    0.495   30 (21.3)    13 (25.5)   1.283 (0.602--2.734)    0.518
  AA                             3 (2.9)          3 (5.4)      1.848 (0.349--9.773)    0.470    2 (1.4)      2 (3.9)    3.003 (0.403--22.390)   0.283
  Dominant (TT vs. TA+AA)                                      0.877 (0.398--1.934)    0.746                            1.378 (0.667--2.846)    0.386
  Recessive (TT+TA vs. AA)                                     2.026 (0.382--10.736)   0.407                            2.675 (0.362--19.768)   0.335

Adjusted by age and gender. NA; not applicable. AOR, adjusted odds ratio. CI, confidence interval.

Moyamoya disease has a bimodal pattern of incidence so we divided the patients into pediatric (\<18 years) and adult (≥18 years) groups. We further divided the moyamoya patients into ischemic or hemorrhagic groups based on clinical and MRI findings. We performed indirect bypass surgery in 64 patients and direct superficial temporal artery to middle cerebral artery bypass plus encephalo-duro-arterio-myo-synangiosis (STA-MCA plus EDAMS) in one patient. We graded newly developed collateral vessels according to the method of Matsushima et al. [@pone.0047158-Matsushima1]. Briefly, Grade A represented synangiosis-induced filling of greater than two-thirds of MCA circulation, Grade B represented between one-third and two-thirds, and Grade C represented less than one-third. We further divided the 64 indirect bypass surgical patients by collateral vessel formation after 2 years into good (collateral grade A) and poor (collateral grade B, C) using MRA. [Table 1](#pone-0047158-t001){ref-type="table"} shows the demographic characteristics of the moyamoya patients and control subjects.

10.1371/journal.pone.0047158.t006

###### Haplotype frequencies of the *VEGF a*nd *KDR* polymorphisms according to age.

![](pone.0047158.t006){#pone-0047158-t006-6}

                                 Age \<18 years   Age ≥18 years                                                                            
  ----------------------------- ---------------- --------------- ----------------------- ------- -------- -------- ----------------------- -------
  *VEGF* −2578/−1154/−634/936                                                                                                              
  CGCC                               0.3502          0.2331       0.566 (0.335--0.957)    0.041   0.3251   0.4350   1.594 (1.001--2.540)    0.053
  CGGC                               0.2894          0.3561       1.365 (0.836--2.231)    0.254   0.2360   0.2047   0.842 (0.484--1.465)    0.584
  AAGC                               0.1234          0.1361       1.107 (0.557--2.199)    0.860   0.1471   0.0406   0.250 (0.087--0.718)    0.006
  CGCT                               0.0910          0.0578       0.551 (0.213--1.423)    0.277   0.0708   0.0741   0.976 (0.400--2.382)    1.000
  AGGC                               0.0840          0.0648       0.733 (0.295--1.826)    0.658   0.1085   0.0587   0.511 (0.207--1.265)    0.171
  CGGT                               0.0233          0.0372       1.474 (0.388--5.606)    0.726   0.0656   0.0620   0.926 (0.357--2.403)    1.000
  AGGT                               0.0152          0.0532       3.792 (0.930--15.470)   0.073   0.0189   0.0310   1.696 (0.398--7.231)    0.440
  CAGC                               0.0109          0.0221       1.836 (0.255--13.220)   0.617     NA       NA              NA              NA
  AAGT                                 NA              NA                  NA              NA     0.0149   0.0368   2.866 (0.703--11.680)   0.216
  *KDR* −604/1192/1719                                                                                                                     
  TGA                                0.4141          0.3786       0.857 (0.534--1.376)    0.550   0.3624   0.3736   1.048 (0.655--1.675)    0.845
  TGT                                0.2187          0.2688       1.293 (0.758--2.204)    0.407   0.2551   0.2337   0.897 (0.528--1.525)    0.689
  CGA                                0.1325          0.1393       1.093 (0.561--2.128)    0.864   0.1990   0.1919   0.984 (0.557--1.740)    0.957
  CGT                                0.0974          0.0794       0.804 (0.353--1.831)    0.687   0.0630   0.0341   0.444 (0.128--1.542)    0.190
  TAT                                0.0773          0.0402       0.549 (0.196--1.541)    0.346   0.0421   0.0495   1.160 (0.398--3.378)    0.786
  CAT                                0.0330          0.0938       3.065 (1.153--8.148)    0.024   0.0618   0.1042   1.884 (0.851--4.173)    0.113

*P-values* after 10,000 permutation test. NA; not applicable. OR, odds ratio. CI, confidence interval.

All participants gave informed written consent prior to enrollment in the study. The institutional review boards of Severance Hospital (4-2008-0308) and CHA Bundang Medical Center (PBC09-103) approved this study.

10.1371/journal.pone.0047158.t007

###### Comparison of the *VEGF* and *KDR* genotype frequencies according to collateral vessel formation score.

![](pone.0047158.t007){#pone-0047158-t007-7}

  Characteristics             Collateral grade A (n = 40)   Collateral grade B and C (n = 24)       AOR (95% CI)        *P* [\*](#nt108){ref-type="table-fn"}
  -------------------------- ----------------------------- ----------------------------------- ----------------------- ---------------------------------------
  *VEGF* −2578C\>A                                                                                                     
  CC                                   20 (50.0)                        13 (54.2)                 1.000 (reference)    
  CA                                   18 (45.0)                        7 (29.2)                0.615 (0.200--1.893)                    0.397
  AA                                    2 (5.0)                         4 (16.7)                3.060 (0.473--19.816)                   0.241
  Dominant (CC vs. CA+AA)                                                                       0.867 (0.313--2.408)                    0.785
  Recessive (CC+CA vs. AA)                                                                      3.757 (0.625--22.590)                   0.148
  *VEGF* −1154G\>A                                                                                                     
  GG                                   27 (67.5)                        17 (70.8)                 1.000 (reference)    
  GA                                   12 (30.0)                        6 (25.0)                0.841 (0.253--2.796)                    0.777
  AA                                    1 (2.5)                          1 (4.2)                1.475 (0.082--26.410)                   0.792
  Dominant (GG vs. GA+AA)                                                                       0.926 (0.297--2.886)                    0.895
  Recessive (GG+GA vs. AA)                                                                      1.565 (0.090--27.244)                   0.759
  *VEGF* −634G\>C                                                                                                      
  GG                                   11 (27.5)                        13 (54.2)                 1.000 (reference)    
  GC                                   22 (55.0)                        7 (29.2)                0.252 (0.076--0.837)                    0.024
  CC                                   7 (17.5)                         4 (16.7)                0.284 (0.045--1.780)                    0.179
  Dominant (GG vs. GC+CC)                                                                       0.286 (0.095--0.859)                    0.026
  Recessive (GG+GC vs. CC)                                                                      0.857 (0.215--3.412)                    0.827
  *VEGF* 936C\>T                                                                                                       
  CC                                   27 (67.5)                        16 (66.7)                 1.000 (reference)    
  CT                                   13 (32.5)                        8 (33.3)                1.069 (0.357--3.206)                    0.905
  TT                                    0 (0.0)                          0 (0.0)                         NA                              NA
  Dominant (CC vs. CT+TT)                                                                       1.069 (0.357--3.206)                    0.905
  Recessive (CC+CT vs. TT)                                                                               NA                              NA
  *KDR* −604T\>C                                                                                                       
  TT                                   17 (42.5)                        11 (45.8)                 1.000 (reference)    
  TC                                   19 (47.5)                        12 (50.0)               0.950 (0.325--2.778)                    0.926
  CC                                   4 (10.0)                          1 (4.2)                0.370 (0.035--3.962)                    0.411
  Dominant (TT vs. TC+CC)                                                                       0.840 (0.298--2.367)                    0.741
  Recessive (TT+TC vs. CC)                                                                      0.346 (0.035--3.409)                    0.363
  *KDR* 1192G\>A                                                                                                       
  GG                                   30 (75.0)                        16 (66.7)                 1.000 (reference)    
  GA                                   8 (20.0)                         7 (29.2)                1.381 (0.401--4.758)                    0.609
  AA                                    2 (5.0)                          1 (4.2)                0.843 (0.063--11.263)                   0.897
  Dominant (GG vs. GA+AA)                                                                       1.355 (0.420--4.375)                    0.612
  Recessive (GG+GA vs. AA)                                                                      0.664 (0.053--8.390)                    0.752
  *KDR* 1719T\>A                                                                                                       
  TT                                   10 (25.0)                        7 (29.2)                  1.000 (reference)    
  TA                                   18 (45.0)                        9 (37.5)                0.786 (0.219--2.824)                    0.712
  AA                                   12 (30.0)                        8 (33.3)                0.886 (0.227--3.462)                    0.861
  Dominant (TT vs. TA+AA)                                                                       0.825 (0.259--2.626)                    0.745
  Recessive (TT+TA vs. AA)                                                                      1.195 (0.398--3.593)                    0.751

Adjusted by age and gender. NA; not applicable. AOR, adjusted odds ratio. CI, confidence interval.

VEGF Genotyping {#s2b}
---------------

We investigated four relevant single nucleotide polymorphism (SNP) candidates in the *VEGF* gene. We used the G-DEX blood extraction kit (iNtRON Biotechnology, Inc., Seongnam, South Korea) according to the manufacturer's instructions for DNA extraction. We obtained all SNP sequences from the HapMap database ([www.hapmap.org](http://www.hapmap.org)) [@pone.0047158-Consortium1]. The *VEGF* -2578C\>A, -1154G\>A, -634G\>C, and 936C\>T polymorphisms were analyzed by polymerase chain reaction--restriction fragment length polymorphism (PCR-RFLP) method.

We used following primers: *VEGF* −2578C\>A polymorphism, forward 5′-GGA TGG GGC TGA CTA GGT AAG-3′ and reverse 5′-AGC CCC CTT TTC CTC CAA C-3′, that amplifies a 308 bp (C allele) or 326 bp (A allele) product; *VEGF* −1154G\>A polymorphism, forward 5′-CGC GTG TCT CTG GAC AGA GTT TCC-3′ and reverse 5′-CGG GGA CAG GCG AGC TTC AG-3′, that amplifies a 173 bp product; *VEGF* −634G\>C polymorphism, forward 5′-CAG GTC ACT CAC TTT GCC CCG GTC-3′ and reverse 5′-GCT TGC CAT TCC CCA CTT GAA TCG-3′, that amplifies a 204 bp product; and *VEGF* 936C\>T polymorphism, forward 5′-AAG GAA GAG GAG ACT CTG CGC AGA GC-3′ and reverse 5′-TAA ATG TAT GTA TGT GGG TGG GTG TGT CTA CAG G-3′, that amplifies a 208 bp fragment.

The *VEGF* −2578C\>A and −634G\>C polymorphisms were identified by digesting the PCR product with the restriction endonuclease *Ava*II (New England Biolabs, Beverly, MA, USA). The *VEGF* −1154G\>A polymorphism was identified by digesting the PCR product with the restriction endonuclease *Mnl*I (New England Biolabs). The *VEGF* 936C\>T polymorphism was identified by digesting the PCR product with the restriction endonuclease *Nla*III (New England Biolabs). All restriction digests were performed at 37°C for 16 h.

KDR Genotyping {#s2c}
--------------

We identified 3 well-known SNPs in the *KDR* gene, including one in the promoter region (−604) and two in the coding region (1192 and 1719). All SNP sequences were obtained from the HapMap database (<http://www.hapmap.org>) [@pone.0047158-Consortium1]. We used previously described primers and PCR-RFLP conditions for *KDR* polymorphism analyses [@pone.0047158-Wang1]. For SNP −604, two DNA fragments (174 bp and 116 bp) were observed for the C allele and one band (290 bp) was produced for the T allele. For the 1192 polymorphism, two DNA fragments (30 bp and 232 bp) indicated the A allele and one band (252 bp) was produced for the G allele. For SNP 1719, two DNA fragments (191 bp and 213 bp) were observed for the A allele and one band (404 bp) was produced for the T allele. The genotyping reproducibility was confirmed by bi-directional sequencing of 400 randomly selected samples.

Measurement of Plasma Total Homocysteine (tHcy), Folic Acid (FA), and Vitamin B12 (VB12) {#s2d}
----------------------------------------------------------------------------------------

Blood was collected from moyamoya patients into a tube containing anticoagulant 12 hours after a meal. The tube was centrifuged for 15 min at 1000 × *g*, and the plasma was separated. The concentration of tHcy (n = 37, 10.18±2.81 µmol/L) in the plasma was measured by fluorescent polarizing immunoassay (FPIA) with IMx (Abbott Laboratories, Chicago, IL, USA). The plasma concentration of FA (n = 30, 10.25±3.50 ng/ml) and VB12 (n = 35, 848.06±319.22 pg/ml) was determined using a radioassay kit (ACS 180; Bayer, Tarrytown, NY, USA).

Measurement of Whole Blood Nitric Oxide (NO) {#s2e}
--------------------------------------------

Blood was collected from moyamoya patients into a tube containing anticoagulant 12 hours after a meal. NO production was evaluated by determining the circulating levels of nitrosyl-hemoglobin complexes. In the present study, the paramagnetic properties of nitrosyl-heme adducts were used to detect whole blood NO-hemoglobin derivatives (n = 33, 5.30±6.93 arbitrary unit \[AU\]) by electron paramagnetic resonance (EPR) spectroscopy.

Statistical Analyses {#s2f}
--------------------

To analyze the demographic characteristics of moyamoya disease, we used the Mann--Whitney and chi-square (χ^2^) tests for continuous and categorical data, respectively. The associations among pediatric and adult patients were estimated by computing the odds ratios (ORs) and 95% confidence intervals (CIs) using Fisher's exact test. The adjusted odds ratios (AORs) for *VEGF* and *KDR* polymorphisms were calculated using multiple logistic regression analyses using gender and age. The genotype distribution of each polymorphism was expected under Hardy-Weinberg equilibrium. Statistical analyses were performed using GraphPad Prism 4.0 (GraphPad Software, Inc., San Diego, CA, USA) and StatsDirect software (version 2.4.4; StatsDirect Ltd., Altrincham, UK). Haplotype analyses were performed using HAPSTAT (version 3.0; University of North Carolina, Chapel Hill, NC, USA) and Haploview 4.2 (Broad Institute, Cambridge, MA, USA). StatsDirect Statistical Software (Version 2.4.4; StatsDirect Ltd, Altrincham, UK) was used to calculate the adjusted OR and 95% CI. The linkage disequilibrium between loci was measured using the absolute value of Lewontin's D [@pone.0047158-Hedrick1].

Results {#s3}
=======

[Figure 1](#pone-0047158-g001){ref-type="fig"} shows the linkage disequilibrium of *VEGF* and *KDR* polymorphisms from the present study. A comparison of genotype frequencies between moyamoya patients and control subjects of the *VEGF* −2578C\>A, −1154G\>A, −634G\>C, and 936C\>T polymorphisms and the *KDR* −604T\>C, 1192G\>A, and 1719T\>A polymorphisms is shown in [Table 2](#pone-0047158-t002){ref-type="table"}. There were no statistically significant differences between moyamoya patients and controls in any of the polymorphisms evaluated ([Tables 2](#pone-0047158-t002){ref-type="table"} and [3](#pone-0047158-t003){ref-type="table"}).

In subgroup analyses ([Tables 4](#pone-0047158-t004){ref-type="table"} and [5](#pone-0047158-t005){ref-type="table"}), the CC genotype of the *VEGF* −634 was less frequent in pediatric moyamoya disease (*p* = 0.040; CC vs. GG) and comparison with the GG+GC genotype was also significantly different in pediatric moyamoya patients. In the adult subgroup, the *VEGF* −634CC genotype was more frequent in moyamoya disease (*p* = 0.024; CC vs. GG). The frequencies of the *KDR* polymorphisms in both the pediatric and adult subgroups were not significantly different.

We conducted haplotype analyses of the *VEGF* and *KDR* polymorphisms ([Table 6](#pone-0047158-t006){ref-type="table"}). The C-G-C-C haplotype (*VEGF* −2578/−1154/−634/936) in pediatric moyamoya patients was significantly different. In addition, the C-A-T haplotype (*KDR* −604/1192/1719) increased the risk of pediatric moyamoya. In adult moyamoya, the A-A-G-C haplotype (*VEGF* −2578/−1154/−634) was significantly different whereas other haplotypes were not. We have estimated and provided several haplotype frequencies in [Table 6](#pone-0047158-t006){ref-type="table"}.

We performed indirect bypass surgery in 64 patients. The genotypes containing the *VEGF* −634C allele had better collateral vessel formation after surgery whereas −634GG was associated with poor collateral grade ([Table 7](#pone-0047158-t007){ref-type="table"}). We also investigated the haplotype frequency differences related to collateral grades. However, there were no statistical differences ([Table S1](#pone.0047158.s001){ref-type="supplementary-material"}). Our results potentially implicate the *VEGF* −634G\>C polymorphism in the development of collateral vessel formation in moyamoya disease. The other *VEGF* and *KDR* polymorphisms we studied did not exhibit statistically significant differences in collateral vessel formation.

To assess the clinical significance of the *VEGF* and *KDR* polymorphisms, we surveyed the association between the studied polymorphisms and various vascular risk factors (tHcy, FA, VB12, and NO). Blood tHcy, FA, VB12, and NO are essential for vascular homeostasis regulation [@pone.0047158-Fabian1]. There were no significant distinctions according to *VEGF* polymorphisms but the *KDR* −604C (*p* = 0.017) and 1192A (*p* = 0.032) alleles were linked to decreased NO levels ([Table S2](#pone.0047158.s002){ref-type="supplementary-material"}). The association of the *KDR* −604 and 1192 polymorphisms with NO levels suggests that *KDR* haplotypes containing −604C or 1192A may adversely affect vascular homeostasis.

Discussion {#s4}
==========

In this study, we found *VEGF* or *KDR* polymorphisms influence moyamoya disease in subgroup analyses as well as the formation of revascularization after bypass surgery. VEGF is involved in vasculogenesis in different intracranial lesions [@pone.0047158-Sakamoto1], is an endothelial cell mitogen that induces transient vascular leakage, and a potent angiogenic factor [@pone.0047158-Thomas1]. *VEGF* promotes angiogenesis in cerebral ischemia [@pone.0047158-Sakamoto1], [@pone.0047158-Issa1] and causes pathologic vessel formation [@pone.0047158-Cao1].

Moyamoya disease is characterized by the angiographic findings of arterial stenosis and occlusion of the circle of Willis [@pone.0047158-Suzuki1]. It can lead to transient ischemic attacks or a cerebral infarction pattern in juveniles [@pone.0047158-Fukui1] and a hemorrhagic stroke pattern in adults [@pone.0047158-Kuroda1], [@pone.0047158-Mineharu2]. Takekawa et al. [@pone.0047158-Takekawa1] reported increased VEGF expression in autopsy specimens from adults with moyamoya disease and Sakamoto et al. reported that the total meningeal cellularity and VEGF expression in the moyamoya dura was significantly higher in moyamoya patients compared to controls [@pone.0047158-Sakamoto1]. Although increased VEGF concentrations have been demonstrated in moyamoya disease [@pone.0047158-Sakamoto1], [@pone.0047158-Takekawa1], the specific role of *VEGF* in moyamoya genetics remains unclear. We therefore reasoned that mutations and genetic polymorphisms of the *VEGF* gene may cause cerebral ischemia in moyamoya disease.

Vascular endothelial growth factor A (VEGF-A) is a disulfide-bonded dimeric glycoprotein that is a member of a protein family that includes VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PGF). The gene that encodes *VEGF-A* is located on human chromosome 6 and comprises a 14-kb coding region with eight exons. *VEGF* cellular signaling activity depends on specific membrane receptors. The receptors include fms like tyrosine kinase-1 (Flt-1 or VEGFR-1), KDR (also known as VEGFR-2) [@pone.0047158-Takahashi1], [@pone.0047158-Soker1], and Flt-4 (also known as VEGFR-3) [@pone.0047158-Harry1], [@pone.0047158-Ferrara1]. VEGF acts on endothelial cells particularly through Flt-1 and KDR [@pone.0047158-Rahimi1], [@pone.0047158-Marchand1]. Epidermal growth factor (EGF) arising from hypoxia stimulates Flt-1 expression and inhibits KDR expression [@pone.0047158-Okuda1].

VEGF binding to KDR activates multiple signaling cascades that affect angiogenesis as well as endothelial cell survival, proliferation, and migration. Recently, several SNPs in the *VEGF* gene have been linked to cancer risk and prognosis [@pone.0047158-Schneider1] and coronary arterial disease [@pone.0047158-Petrovic1], indicating the importance of the VEGF-KDR signaling pathway in human disease. Oh et al. reported the SNP 1719T allele conferred ischemic stroke risk in a dose dependent manner [@pone.0047158-Oh1].

Revascularization after bypass surgery and the formation of new pial vessels may play a role in moyamoya disease. Several studies have suggested that endogenous VEGF production mediates compensatory revascularization during various physiological and pathological processes [@pone.0047158-Issa1], [@pone.0047158-Marti1], [@pone.0047158-Kuo1], [@pone.0047158-Dvorak1].

In addition, as suggested by the data in our study, *VEGF* −634 G\>C may be a possible prognostic biomarker after bypass surgery. Taken together, we can speculate that *VEGF* polymorphisms influence moyamoya disease as well as the formation of synangiosis-induced collateral vessel after bypass surgery. Although revascularization with pial synangiosis helps ameliorate ischemic symptoms, some patients progress to cerebral infarction or hemorrhage, even after surgery. This likely reflects the degree of synangiosis and is dependent on the genetic characteristics of the patient. Therefore, *VEGF* or *KDR* polymorphisms can be used as prognostic factors after revascularization surgery.

There are some limitations in correlating *VEGF* or *KDR* polymorphisms with our clinical findings. Our data should be interpreted with caution because of the relatively small sample size. Patients require long-term follow up to assess clinical outcomes and variation in the clinical characteristics of moyamoya disease makes it difficult to identify specific genes that are associated with the disease. In addition, moyamoya disease is characterized by genetic heterogeneity and complex interactions between genes and other factors. Although there are limitations with sample size and long-term follow-up clinical findings, it is important to determine the relationship of *VEGF* or *KDR* polymorphisms with moyamoya disease and collateral vessel formation after surgery.

In summary, no differences in *VEGF −*2578, −1154, −634, and 936 or *KDR* −604, 1192, and 1719 polymorphisms were observed between total moyamoya disease patients and control subjects. However, in subgroup analyses, we found that the CC genotype in *VEGF −*634 occurred less frequently in pediatric patients (*p* = 0.040) and occurred more often in adult moyamoya patients (*p* = 0.024). The genotypes including the *VEGF* −634C allele had better collateral vessel formation after surgery. In addition, the C-G-C-C (*VEGF* −2578/−1154/−634/936) haplotype and the C-A-T (*KDR* -604/1192/1719) haplotype in pediatric patients, as well as the A-A-G-C (*VEGF* −2578/−1154/−634/936) in adult moyamoya patients, had significant differences. Therefore, these results suggest that *VEGF* or *KDR* polymorphisms influence moyamoya disease as well as the formation of synangiosis-induced collateral vessel after bypass surgery.

Supporting Information {#s5}
======================

###### 

**Haplotype analyses of** ***VEGF*** **and** ***KDR*** **polymorphisms according to collateral score.** \**P-values* after 10,000 permutation test.

(DOC)

###### 

Click here for additional data file.

###### 

**Association of** ***VEGF*** **and** ***KDR*** **polymorphisms with vascular risk factors.** \**P-values* between major and minor alleles of each polymorphism analyzed by Mann-Whitney test. AU; arbitrary units.

(DOC)

###### 

Click here for additional data file.

We thank all the people who give the help for this study.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: YSP DSK NKK. Performed the experiments: YSP YJJ HSK. Analyzed the data: YSP YJJ. Contributed reagents/materials/analysis tools: YSP SHO HSK WCK OJK TGK IBH JUC DSK. Wrote the paper: YSP YJJ DSK NKK.
